Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 09:43AM ET
7.46
Dollar change
+0.07
Percentage change
0.99
%
IndexRUT P/E- EPS (ttm)-1.39 Insider Own33.38% Shs Outstand61.77M Perf Week27.15%
Market Cap461.02M Forward P/E- EPS next Y-1.55 Insider Trans0.00% Shs Float41.16M Perf Month13.77%
Income-71.17M PEG- EPS next Q-0.35 Inst Own60.15% Short Float5.79% Perf Quarter65.86%
Sales0.00M P/S- EPS this Y-4.17% Inst Trans-1.31% Short Ratio4.47 Perf Half Y65.12%
Book/sh2.27 P/B3.28 EPS next Y-8.71% ROA-41.86% Short Interest2.38M Perf Year70.79%
Cash/sh3.05 P/C2.44 EPS next 5Y13.10% ROE-54.98% 52W Range2.69 - 7.56 Perf YTD75.20%
Dividend Est.- P/FCF- EPS past 5Y-35.73% ROI-38.23% 52W High-1.28% Beta1.36
Dividend TTM- Quick Ratio13.36 Sales past 5Y0.00% Gross Margin- 52W Low177.56% ATR (14)0.44
Dividend Ex-Date- Current Ratio13.36 EPS Y/Y TTM28.16% Oper. Margin0.00% RSI (14)71.25 Volatility9.03% 7.40%
Employees59 Debt/Eq0.33 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price21.00
Option/ShortYes / Yes LT Debt/Eq0.33 EPS Q/Q24.03% Payout- Rel Volume0.79 Prev Close7.39
Sales Surprise- EPS Surprise-3.58% Sales Q/Q- EarningsMar 12 BMO Avg Volume533.18K Price7.46
SMA2021.96% SMA5031.65% SMA20056.94% Trades Volume34,304 Change0.99%
Date Action Analyst Rating Change Price Target Change
Mar-23-23Upgrade Jefferies Hold → Buy $4.50 → $6
May-26-22Initiated Jefferies Hold $5
Feb-07-22Initiated H.C. Wainwright Buy $33
Nov-29-21Initiated Needham Buy $23
Aug-18-20Initiated Wedbush Outperform $35
Aug-18-20Initiated Piper Sandler Overweight $40
Aug-18-20Initiated Cowen Outperform
Aug-18-20Initiated BofA Securities Buy $33
Mar-26-24 08:30AM
Mar-12-24 08:30AM
Feb-26-24 08:30AM
Feb-06-24 08:30AM
Dec-05-23 08:30AM
08:30AM Loading…
Nov-09-23 08:30AM
Nov-07-23 08:30AM
Nov-03-23 04:15PM
Oct-26-23 08:30AM
Oct-14-23 12:07PM
Oct-10-23 12:00PM
08:30AM
Oct-06-23 08:30AM
Sep-26-23 07:30AM
Sep-20-23 08:30AM
08:30AM Loading…
Sep-06-23 08:30AM
Sep-05-23 08:30AM
Aug-08-23 08:30AM
Aug-07-23 10:50AM
Aug-03-23 04:01PM
Aug-01-23 04:01PM
Jul-27-23 11:20PM
04:33PM
Jul-26-23 07:30AM
Jul-19-23 08:30AM
Jul-14-23 08:34AM
Jun-27-23 08:30AM
Jun-15-23 12:53PM
Jun-02-23 07:30AM
May-09-23 08:30AM
08:30AM Loading…
May-03-23 08:30AM
Apr-16-23 09:01AM
Apr-14-23 08:30AM
Apr-11-23 08:30AM
Apr-04-23 08:30AM
Mar-28-23 09:04AM
Mar-22-23 08:30AM
Mar-16-23 08:50AM
Mar-01-23 08:30AM
Feb-16-23 08:59AM
07:30AM
Feb-06-23 07:30AM
Feb-04-23 07:04AM
Jan-09-23 08:30AM
Dec-05-22 08:30AM
Dec-01-22 07:30AM
Nov-10-22 08:30AM
Nov-07-22 07:30AM
Nov-06-22 09:37AM
Nov-03-22 07:30AM
Oct-31-22 07:30AM
Sep-26-22 06:17AM
Sep-06-22 07:30AM
Aug-24-22 12:24PM
Aug-23-22 12:42PM
Aug-18-22 11:00AM
Aug-17-22 12:27PM
Aug-15-22 07:30AM
Aug-12-22 11:39AM
Jul-26-22 07:30AM
Jul-20-22 10:56AM
Jul-19-22 04:30PM
Jun-24-22 09:55AM
Jun-16-22 07:30AM
Jun-07-22 07:30AM
Jun-01-22 07:30AM
May-28-22 08:07AM
May-10-22 07:30AM
May-06-22 05:30PM
May-03-22 07:30AM
Apr-28-22 06:39AM
Apr-25-22 09:23PM
Apr-18-22 12:32PM
Apr-14-22 08:16AM
Apr-12-22 07:30AM
Apr-06-22 07:30AM
Apr-04-22 07:30AM
Mar-15-22 05:24PM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-10-22 11:51AM
Nov-15-21 07:30AM
Nov-12-21 10:29AM
Nov-11-21 07:30AM
Nov-09-21 04:05PM
Oct-23-21 10:40AM
Oct-04-21 07:30AM
Sep-22-21 07:30AM
Sep-14-21 12:09PM
Aug-11-21 06:00AM
Aug-04-21 07:30AM
Jul-13-21 07:30AM
Jun-09-21 07:30AM
May-12-21 06:00AM
May-07-21 07:30AM
May-06-21 07:30AM
Apr-29-21 07:30AM
Apr-28-21 07:30AM
Apr-26-21 04:20AM
Apr-14-21 07:30AM
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hopfner Robert LorneDirectorAug 01 '23Buy4.80833,3333,999,9982,923,110Aug 03 08:01 PM
Pivotal bioVenture Partners FuDirectorAug 01 '23Buy4.80833,3333,999,9982,923,110Aug 03 08:13 PM
Hopfner Robert LorneDirectorMay 12 '23Buy6.25228,7021,429,3883,661,518May 15 05:06 PM
Hopfner Robert LorneDirectorMay 11 '23Buy6.48219,2301,420,6103,432,816May 15 05:06 PM
Hopfner Robert LorneDirectorMar 29 '23Buy4.54344,5921,563,7243,213,586Mar 30 05:46 PM